Regulatory Review of New TED Drug | Thyroid Foundation Of Canada

 

Regulatory Review of New TED Drug

TFC is supporting the Canadian regulatory review of the teprotumumab (Tepezza) drug for treating Thyroid Eye Disease produced by Amgen biopharmaceuticals.

This review is part of the standard Health Technology Assessment process established by Canada’s Drug Agency (CDA) for the approval of new drugs.  We were approached by Amgen this summer to assist them with this effort and we are working with a third party, Eversana, to develop and compile a survey and CDA submission for approval of their teprotumumab (Tepezza) product in Canada.

The complete Health Assessment Report can be viewed at: SR0853-teprotumumab_Patient_Clinician_Input.pdf.

It makes for a most interesting read!

Read the detailed article about this review in the fall issue of our Thyrobulletin newsletter.

Help us to Help Others

Awareness/Education

  • Community publicity & advocacy
  • Educational webinars
  • Information resources on our website

Patient Support

  • Toll Free Help line and email
  • Website thyroid news
  • Thyrobulletin newsletter

Research

  • Annual Thyroid Research grants
  • Thyroid research news
  • Thyroid research articles